Back to Results

Sandoz Group AG (SDZXF)

Featured in Bullish Trend Stocks

Sandoz Group AG is a healthcare company focused on generic medicines and biosimilars for global markets. Its portfolio spans a broad range of therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory care, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. The company also supplies active pharmaceutical ingredients and finished dosage forms. Founded in 1886 and headquartered in Basel, Switzerland, Sandoz Group AG’s common shares trade on OTC Markets under the symbol SDZX.F.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-SDZX.F
$75.85
-5.7% Downside
Fair
Not available
Not available
Great
1.3%
October 28, 2026
55.8x
4.0x
3.1x
36.124 B
39.882 B
14.8%
95.8%
6.8
68.9%
214.6%
Valuation • Fair Value

Sandoz Group AG (OTC-SDZX.F) Fair Value by Valuation Model

Review the available estimates for Sandoz Group AG (OTC-SDZX.F), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$75.85

Estimated downside of 5.7% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$89.04

Discounted cash flow valuation reference.

Ben Graham Formula Value

$16.57

Classic Ben Graham valuation formula reference.

DDM Fair Value

$45.50

Dividend discount model valuation reference.

EPV Fair Value

$46.71

Earnings power value estimate.

Comps Fair Value

$72.56

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 7 available valuation references for Sandoz Group AG (OTC-SDZX.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Sandoz Group AG (OTC-SDZX.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

11.676 B

Current operating scale indicator.

Revenue Forecast

12.086 B

Forward revenue estimate.

EBITDA

1.574 B

Current operating profitability reference.

EBITDA Forecast

2.753 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Sandoz Group AG (OTC-SDZX.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Sandoz Group AG (OTC-SDZX.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.71

No elevated caution signal from this screen.

Altman Z-Score

6.8

Relatively strong balance-sheet zone.

FCF / Net Income

214.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Sandoz Group AG (OTC-SDZX.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Sandoz Group AG (OTC-SDZX.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 28, 2026

Days to Earnings

40

Dividend Yield

1.3%

Current income yield reference.

Payout Ratio

68.9%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Sandoz Group AG (OTC-SDZX.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Sandoz Group AG (OTC-SDZX.F) Stock Forecast & Technical Outlook

Review Sandoz Group AG (OTC-SDZX.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Sandoz Group AG (OTC-SDZX.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Sandoz Group AG (OTC-SDZX.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Sandoz Group AG (OTC-SDZX.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Sandoz Group AG (OTC-SDZX.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Sandoz Group AG (OTC-SDZX.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Sandoz Group AG (OTC-SDZX.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Sandoz Group AG (OTC-SDZX.F) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Sandoz Group AG (OTC-SDZX.F) Stock FAQ

Data-supported answers about Sandoz Group AG (OTC-SDZX.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$75.85
Estimated downside 5.7%
Valuation Rating
Overvalued
Estimated downside of 5.7%
Financial Health
Great
Current financial-health read

The current fair value estimate for Sandoz Group AG (OTC-SDZX.F) is $75.85. This implies an estimated downside of 5.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 5.7% versus the current market price.

The current financial health read for Sandoz Group AG (OTC-SDZX.F) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Sandoz Group AG (OTC-SDZX.F) is October 28, 2026.

Based on the current data, dividend yield is 1.3%.

The current P/E ratio listed for Sandoz Group AG (OTC-SDZX.F) is 55.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Sandoz Group AG is 36.124 B.

The current enterprise value listed for Sandoz Group AG is 39.882 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Sandoz Group AG is OTC-SDZX.F, and the stock is listed on OTC Markets.

Sandoz Group AG (OTC-SDZX.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Sandoz Group AG is 14.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Sandoz Group AG is 95.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B